Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis. - Wikidata - awgldk - TriplyDB

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis.

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis.

http://www.wikidata.org/entity/Q35075402

about

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis.

http://www.wikidata.org/entity/Q35075402

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Bevacizumab versus ranibizumab ...... degeneration: a Meta-analysis.

@ast

Bevacizumab versus ranibizumab ...... degeneration: a Meta-analysis.

@en

type

label

Bevacizumab versus ranibizumab ...... degeneration: a Meta-analysis.

@ast

Bevacizumab versus ranibizumab ...... degeneration: a Meta-analysis.

@en

prefLabel

Bevacizumab versus ranibizumab ...... degeneration: a Meta-analysis.

@ast

Bevacizumab versus ranibizumab ...... degeneration: a Meta-analysis.

@en

P1433

Q35075402-61902460-21AB-4A70-BFF2-43ECC3F926FF

P1476

Q35075402-E2C7FAA0-0303-4979-92FC-B84594C28281

P2093

Q35075402-31224954-02E6-49AA-B64C-31703E2A3A80

Q35075402-4583BEBE-8C6F-4CE1-91C8-C7E0588F435D

Q35075402-7251A25A-32A6-4571-A56F-7B5F1FFF7C4F

Q35075402-A079FD02-9734-4230-8CCE-FCB1B4E51547

Q35075402-C5EE3B9C-1732-4C52-976D-74CD7C9B9172

Q35075402-D12F066E-41FF-40F1-8549-BC3716ECC641

Q35075402-FAB1800D-61DF-4DF1-AE35-4051FA06748D

P2860

Q35075402-089F1F9E-1AB3-42DC-B868-4A4717AE1CDC

Q35075402-10D84A9E-D5B0-4C80-A4F5-4A7CF8644569

Q35075402-1B07E140-B884-49EB-B97C-DD6238C6BF42

Q35075402-202222E5-4D9E-49A9-BEDA-6044362C289B

Q35075402-2932F2C8-AF36-4426-86A4-B380D5B23B53

Q35075402-2ABCA908-D784-4D78-B5F7-81930B7EEB9A

Q35075402-3BE8B82C-538B-459D-8CE3-8CCCE0E721C4

Q35075402-46ABD502-7A9F-480C-A612-91D74D7D925E

Q35075402-52728B06-9695-4883-B257-CADF103BC1B1

Q35075402-60561115-B5A9-4414-BE10-C895E1D8A054

P304

Q35075402-2A93B591-37AD-41B3-B32E-FE9E40A893BF

P31

Q35075402-13B3C1C5-74EF-4444-9828-9AD62C79187E

P356

Q35075402-54F0CBF4-2C89-4F4B-93DD-A5DCB38A6ECA

P433

Q35075402-F1B20201-2010-45EB-9FB0-3478D2786F78

P478

Q35075402-A78407A5-BCE2-4240-A42E-9727A07AC21B

P577

Q35075402-A87DD594-EAF1-4080-ABBE-9A8ACAA119F8

P698

Q35075402-805ACB14-26CD-424D-B59B-97D339DDFCE0

P921

Q35075402-F248C459-FE2C-42CF-9BF2-0ECD273F42BE

P932

Q35075402-6ADF71E4-8B0B-4F49-ACB7-7C787C04382A

P356

J.ISSN.2222-3959.2015.01.26

P1433

International Journal of Ophthalmology

P1476

Bevacizumab versus ranibizumab ...... degeneration: a Meta-analysis.

@en

P2093

Jian Chen

http://www.w3.org/2001/XMLSchema#string

Min Yao

http://www.w3.org/2001/XMLSchema#string

Qing Zhou

http://www.w3.org/2001/XMLSchema#string

Wen-Jie Wang

http://www.w3.org/2001/XMLSchema#string

Xiao-Ling Zhang

http://www.w3.org/2001/XMLSchema#string

Xiao-Yong Liu

http://www.w3.org/2001/XMLSchema#string

Yi-Xin Qu

http://www.w3.org/2001/XMLSchema#string

P2860

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Angiogenesis as a therapeutic target

Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment.

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

P304

138-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3980/J.ISSN.2222-3959.2015.01.26

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25709924

http://www.w3.org/2001/XMLSchema#string

P921

P932

4325258

http://www.w3.org/2001/XMLSchema#string